Novocure Ltd

NASDAQ NVCR

Download Data

Novocure Ltd Retained Earnings To Equity Ratio 3 year CAGR for the year ending December 31, 2023: 27.09%

Novocure Ltd Retained Earnings To Equity Ratio 3 year CAGR is 27.09% for the year ending December 31, 2023, a 268.19% change year over year. The retained earnings to equity ratio measures the proportion of a company's retained earnings to its shareholders' equity. It is calculated by dividing the retained earnings by the shareholders' equity. This ratio provides insights into the company's reinvestment of earnings and the level of retained profits relative to shareholders' equity. A higher ratio suggests a higher proportion of earnings being retained for reinvestment or future distribution to shareholders. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Novocure Ltd Retained Earnings To Equity Ratio for the year ending December 31, 2022 was -1.76, a -5.60% change year over year.
  • Novocure Ltd Retained Earnings To Equity Ratio for the year ending December 31, 2021 was -1.67, a -26.18% change year over year.
  • Novocure Ltd Retained Earnings To Equity Ratio for the year ending December 31, 2020 was -1.32, a 55.69% change year over year.
  • Novocure Ltd Retained Earnings To Equity Ratio for the year ending December 31, 2019 was -2.99, a 47.88% change year over year.
NASDAQ: NVCR

Novocure Ltd

CEO Mr. William F. Doyle
IPO Date Oct. 2, 2015
Location Jersey
Headquarters No. 4 The Forum, Saint Helier, Jersey, JE2 4UF
Employees 1,453
Sector Healthcare
Industry Medical devices
Description

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Similar companies

INMD

InMode Ltd

NA

NA

IRTC

iRhythm Technologies Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email